{"entity":{"id":"nct06936527","kind":"trial","name":"XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation","aka":["XS-03-II201"],"tldr":"A phase 1/2 trial in colorectal cancer, run by NovaOnco Therapeutics Co., Ltd., now recruiting.","summary":"XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation is a phase 1/2, randomised interventional study registered as NCT06936527 by NovaOnco Therapeutics Co., Ltd., with a registry enrolment figure of 102 participants, started 2025-05-23 and due to reach its primary completion in 2028-04-30. Interventions recorded: Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI; Drug: XS-03; Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI. Conditions listed: Colorectal Cancer; Metastatic Colorectal Cancer With RAS Mutation. Primary outcome: Phase 1b: Number of participants with Dose-limiting Toxicities (DLTs) in experimental arm of XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab; Phase 1b: Determine the Maximum Tolerated Dose (MTD) in experimental arm of XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab; Phase 2: . Colorectal eligibility wording from the registry: \"Patients with histologically and/or cytologically confirmed metastatic colorectal cancer who are not suitable for surgical treatment\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06936527","url":"https://clinicaltrials.gov/study/NCT06936527"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06936527","phase":"1/2","setting":"An Open-label, Multicenter Phase Ib/II Clinical Study: Aim to Valuate the Efficacy and Safety of XS-03 Comination With FOLFOX or FOLFIRI and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation","sponsor":"NovaOnco Therapeutics Co., Ltd.","enrolled":102,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06936527/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}